|
|
| 27.19 Data as of Apr 15 |  0.00 / 0.00%Today’s Change | 26.04 Today|||52-Week Range 42.96 | -23.73% Year-to-Date |
| Previous close | 27.19 |
| Today’s open | 27.23 |
| Day’s range | -- - -- |
| Volume | 1,841,805 |
| Average volume (3 months) | 999,195 |
| Market cap | $3.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -735.00% |
| Earnings growth (this year) | +27.20% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | -96.50% |
| P/E ratio | NM |
| Price/Sales | 767.43 |
| Price/Book | 10.44 |
| Today’s change | Today’s % change | |
|---|---|---|
| MYGNMyriad Genetics Inc | +0.64 | +1.68% |
| NPSPNPS Pharmaceuticals ... | -0.12 | -0.51% |
| MNKDMannkind Corp | -0.01 | -0.16% |
| MNKMallinckrodt Plc | +0.44 | +0.72% |
| Next reporting date | April 24, 2014 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $4.8M |
| Annual profit (last year) | -$170.7M |
| Net profit margin | -3,587.66% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Rick E. Winningham |
Senior Vice President- Operations Frank C. Pasqualone |
Corporate headquarters South San Francisco, California |
.
